NCT02231866View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

August 27, 2014

Primary Completion Date

April 5, 2017

Study Completion Date

April 5, 2017

Conditions
Healthy Adult Immune Responses to Vaccine
Interventions
BIOLOGICAL

VRC-EBOADC069-00-VP

cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan

BIOLOGICAL

VRC-EBOADC076-00-VP

cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire

Trial Locations (3)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

30030

Hope Clinic - Emory Vaccine Ctr, Decatur

21201-1595

University of Maryland Center for Vaccine Development, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02231866 - Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults | Biotech Hunter | Biotech Hunter